FDA's Embrace of AI to Speed Up Drug Approvals Leaves Industry Observers Excited, Uneasy By Law.com's Legal Tech News June 6, 2025 Email this postTweet this postLike this postShare this post on LinkedIn “There are problems with generative AI, and there need to be guardrails and there needs to be human oversight,” said Jason Conaty, counsel at Hogan Lovells.
